Genetic toxicology testing is designed to evaluate the compounds that induce genetic mutations or chromosomal damage.
Genetic toxicology testing is designed to evaluate the compounds that induce genetic mutations or chromosomal damage. Since DNA reactive substances can stimulate carcinogenic processes, such screening strategies aid in assessing compounds having potential human risk. Based on test type, the market can be segmented into in-vitro and in-vivo types. Here, in-vitro type has applications in personalized medicine and drug discovery whereas humanized models for in-vivo experiments are also gaining traction. To meet the high potential for in-vivo testing, key companies are venturing into development of new animal models. For instance, in July 2022, Creative Biogene launched its Zebrafish disease model to support drug discovery and toxicology testing.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39452
Furthermore, there is an expansion of lab facilities and funding globally for increasing the service availability in the market. For instance, in November 2021, Gentronix raised funding of USD 854 thousand (£700 thousand) that has helped in expanding its laboratory facilities by increasing its capacity for genetic, ocular, and skin toxicology testing. There has also been an increasing focus on reduction in animal usage to reduce the costs and time required for assessment of genotoxic potential of substances. This has enhanced the growth opportunities for in-vitro testing capabilities and can significantly boost the market expansion activities. For instance, in July 2022, Inotiv Inc. expanded its capacity for conducting in-vitro cytogenetics and bacterial assays of genetic toxicology studies required in development of novel therapeutics.
Based on products market is segmented into:
- Reagents & Consumables
- Assays
- Services
Increasing drug development activities have accelerated the usage of reagents & consumables in various industries such as pharmaceuticals, biotechnology among others. Similarly, expansion in genetic toxicology testing assays offered by key players is likely to fuel the market growth. For instance, in January 2019, Charles River Laboratories and Toxys expanded the ToxTracker suite of assays in North America. Furthermore, novel launches of various services aid in diagnostic clinical development. For instance, in June 2021, STEMart launched medical device genetic toxicology testing, including, Micronucleus Assay, In-Vitro Mouse Lymphoma Assay TK, Bacterial Reverse Mutation Test (Ames), and In-Vitro Chromosome Aberration Test. Thus, novel advancements in genetic toxicology services are expected to augment the market growth in the near future.
Key Players
- Thermo Fisher Scientific, Inc.
- Laboratory Corp of America Holdings
- Charles River Laboratories International
- Eurofins Scientific
- Merck KGAA
- Jubilant Life Sciences Ltd
- Gentronix Ltd
- Creative Bioarray
- MB Research Laboratories
- Sotera Health LLC.
Market Segmentation
- By Type
- In vitro
- In vivo
- By Product
- Reagents & Consumables
- Assays
- Services
- By Application
- Healthcare Industry (Pharmaceutical, Biotechnology)
- Food Industry
- Agricultural
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39452
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333